Introduction
============

Aortic aneurysms cause around 15 000 deaths a year in the United States, and 40% of these deaths are in women.[@ref1] Most result from abdominal aortic aneurysm, which are several times more common in men[@ref2] [@ref3] [@ref4] [@ref5] [@ref6] but are more deadly in women.[@ref7] [@ref8] The aetiology of aortic aneurysm and the reasons for these sex differences remain unknown. Most studies of abdominal aortic aneurysm have focused primarily on men, and little reliable information is available for women. Previous studies have generally included too few women with aneurysms to generate robust multivariable models and, perhaps as a result, have been inconsistent with respect to several factors and unable to determine whether the negative association with diabetes observed in men also occurs in women.[@ref2] [@ref3] [@ref6] [@ref9] [@ref10] [@ref11] [@ref12]

A better understanding of the factors associated with aortic aneurysms in women would allow more accurate assessment of sex differences and might improve diagnostic vigilance and provide insights into pathophysiology. The women's health initiative was a large complex clinical investigation of strategies for long term prevention of common diseases involving 161 808 women at 40 clinical centres and comprising a set of overlapping clinical trials and an observational study.[@ref13] [@ref14] We assessed the associations between potential risk factors and subsequent clinically important abdominal aortic aneurysm events (rupture and repair) in postmenopausal women.

Methods
=======

This analysis included all 161 808 women enrolled in the women's health initiative clinical trial (68 132) or observational study (93 676). Eligible women were postmenopausal, aged 50-79 at entry, had an expected survival of at least three years, and could be expected to adhere to the protocol. Women were enrolled during 1993-8 and followed up until the end of the main study in 2004-5. The study population, recruitment methods, baseline data collection, enrolment, and follow-up procedures have been previously reported.[@ref13] [@ref14] The protocol and consent forms were approved by the institutional review boards of the participating institutions, and written informed consent was obtained from all participants.

Except for the prospective identification of abdominal aortic aneurysm events (described below), the data used in this analysis were obtained at the time of enrolment. Participants were asked if a doctor had ever told them that they had each condition considered, including a previous diagnosis of abdominal or thoracic aortic aneurysm. There was no confirmation of these baseline reports. Height, weight, waist circumference, and blood pressure were measured directly.

For this analysis, we classified hypertension as blood pressure \>140/90 or use of anti-hypertensive drugs at entry. Coronary artery disease included history of myocardial infarction, angina, or coronary revascularisation. Cerebrovascular disease included history of stroke, transient ischaemic attack, or carotid revascularisation. Peripheral artery disease included "claudication or peripheral artery disease (poor blood flow to the legs or blocked or narrowed arteries to the legs)." Drugs for high cholesterol included both current and past use. Venous thromboembolism included history of deep venous thrombosis or pulmonary embolus. Chronic obstructive pulmonary disease included emphysema and chronic bronchitis. Non-skin cancer also included melanoma.

An abdominal aortic aneurysm event was recorded when a participant was admitted to hospital during the study period with an aneurysm that was symptomatic or required intervention (such as vascular or surgical procedure), or both, and had a diagnostic or interventional procedure that demonstrated the aneurysm. These events were identified when participants or their proxies completed standardised questionnaires (every six months for participants in the clinical trial and every year for those in the observational study) that asked about all admissions since the last update. A centrally trained local physician reviewed relevant medical records to ensure that the event met the criteria described above. Because a symptomatic abdominal aortic aneurysm nearly always represents rupture, these events should essentially all be ruptures and repairs (either elective or emergent).

We performed multiple logistic regression with SAS version 9.1. Missing responses were treated as "no" for specific diseases, including prevalent aortic aneurysm. We included an indicator variable (not shown) for missing values of "dugs for high cholesterol" because this question was not asked in the early months of the study (nor were cholesterol concentrations measured or women asked about high cholesterol). We excluded participants with missing responses to other variables, including hypertension. The model was adjusted for participation in the clinical trial and assigned treatment. We used Pearson correlation coefficient to evaluate correlations between covariates and ran additional models to evaluate potential interactions between strong predictors.

Results
=======

At entry into the study, 301 women reported that they had been told by a doctor that they had aortic aneurysm. During follow-up (mean 7.8 years, median 7.9 years), 184 abdominal aortic aneurysm events were reported, 18 in the women who had reported a diagnosis of aortic aneurysm at entry, resulting in 467 women (0.3%) with aortic aneurysm before or during the study. Fourteen of the 184 women who had abdominal aortic aneurysm events died within five days of the event; all 14 deaths were attributed to "other cardiovascular cause," the category under which deaths related to aneurysm should be coded. Table 1 shows characteristics of the women with and without events[](#tbl1){ref-type="table"}. Our study population had lower rates of current smoking and most diseases than in women in previous screening studies of abdominal aortic aneurysm.[@ref2] [@ref3] [@ref9]

###### 

 Characteristics at time of enrolment of women with and without abdominal aortic aneurysm (AAA) events. Figures are percentages of women unless stated otherwise

  Characteristic\*                        AAA event (n=184)   No event (n=161 624)
  --------------------------------------- ------------------- ----------------------
  Mean (SD) age (years)                   67.2 (6.2)          63.2 (7.2)
  White                                   86.4                82.5
  Black                                   8.2                 9.0
  Mean (SD) height (cm)                   162.2 (6.2)         161.8 (6.7)
  Mean (SD) weight (kg)                   73.0 (17.2)         73.6 (16.9)
  Mean (SD) waist circumference (cm)      88.8 (13.9)         86.5 (13.8)
  Ever smoked (≥100 cigarettes)           82.6                48.4
  Mean (SD) pack years of smokers         44.0 (28.6)         21.0 (22.2)
  Current smoker                          38.0                6.9
  Hypertension                            62.5                38.9
  Drugs for high cholesterol              27.7                13.3
  Coronary artery disease                 26.6                6.8
  Cerebrovascular disease                 9.2                 3.2
  Peripheral artery disease               12.0                2.0
  Venous thromboembolism                  3.3                 3.9
  Diabetes mellitus                       4.3                 5.9
  Chronic obstructive pulmonary disease   12.0                3.5
  Non-skin cancer                         10.3                9.2
  Previous diagnosis of aortic aneurysm   9.8                 0.2
  Postmenopausal hormone therapy:                             
   Current                                19.6                40.1
   Past                                   18.5                16.1
  Alcohol use:                                                
   Never                                  7.1                 10.9
   Past drinker                           28.3                18.6
   \<1 drink/week                         28.8                32.7
   1-- \<7 drinks/week                    20.1                25.5
   ≥7 drinks/week                         15.2                11.6

Table 2 shows multivariable odds ratios for the various factors for abdominal aortic aneurysm events[](#tbl2){ref-type="table"}. The ratio of events to covariates is higher than the 8:1 needed for robust logistic regression modelling.[@ref15] After we eliminated waist circumference because of high correlation with weight, the highest remaining correlation (other than those between smoking variables) was 0.26 for height and weight. Women excluded for missing values were otherwise similar to those included for all characteristics examined.

###### 

 Multivariable model\* of factors associated with abdominal aortic aneurysm event

  Factor†                                 Odds ratio (95% CI)
  --------------------------------------- ----------------------
  No of women with/without an event‡      164/147 885
  Age (per 10 years)                      1.77 (1.37 to 2.29)
  Black race (*v* white)                  0.77 (0.43 to 1.38)
  Other race (*v* white)                  1.23 (0.63 to 2.39)
  Height (per 10 cm)                      1.50 (1.15 to 1.96)
  Weight (per 10 kg)                      0.96 (0.86 to 1.07)
  Ever smoked (≥100 cigarettes)           1.94 (1.16 to 3.24)
  Current smoker (*v* past smoker)        4.19 (2.93 to 6.01)
  Pack years (per 5 pack years)           1.11 (1.08 to 1.14)
  Hypertension (\>140/90 or medication)   2.14 (1.51 to 3.03)
  Drugs for high cholesterol              1.66 (1.15 to 2.39)
  Coronary artery disease                 2.38 (1.61 to 3.51)
  Cerebrovascular disease                 1.15 (0.66 to 2.00)
  Peripheral artery disease               1.81 (1.05 to 3.11)
  Venous thromboembolism                  0.58 (0.25 to 1.34)
  Diabetes mellitus                       0.29 (0.13 to 0.68)
  Chronic obstructive pulmonary disease   1.44 (0.88 to 2.37)
  Non-skin cancer                         0.94 (0.57 to 1.56)
  Previous diagnosis of aortic aneurysm   9.00 (4.71 to 17.20)
  Current hormone therapy (*v* never)     0.48 (0.31 to 0.73)
  Past hormone therapy (*v* never)        0.76 (0.50 to 1.14)
  Current alcohol use (*v* never)         0.73 (0.39 to 1.36)
  Past alcohol use (*v* never)            0.95 (0.49 to 1.83)

\*Model also adjusted for participation in clinical trial and assigned treatment.

†Status at time of enrolment.

‡After exclusion of women with missing values.

Abdominal aortic aneurysm events were strongly associated with age and smoking and, as expected, with previous diagnosis of aortic aneurysm. There were negative associations with diabetes and with baseline use of postmenopausal hormone therapy. Positive associations with abdominal aortic aneurysm events were also seen for height, hypertension, use of cholesterol lowering drugs, and coronary and peripheral artery disease.

There was a significant interaction between smoking and diabetes (P\<0.005), such that diabetes amplified the increased risk from smoking of having an event. When we compared current smoking with never smoking in a model that included pack years and all other variables, the odds ratio (95% confidence interval) for abdominal aortic aneurysm events was 8.73 (5.04 to 15.12).

When we used duration of hormone therapy rather than current or past status, the odds ratio for having an abdominal aortic aneurysm event for up to five years' use was 0.69 (0.46 to 1.04) and for more than five years' use was 0.52 (0.34 to 0.78).

As shown in table 2, the small group of women who never used alcohol were not at reduced risk of aneurysm events.[](#tbl2){ref-type="table"} In other models, we separately compared those reporting seven or more alcohol drinks a week, one to fewer than seven drinks a week, or past use with a control group of women who never used alcohol or had less than one drink a week, and found no significant associations of alcohol use with aortic aneurysm events.

Discussion
==========

In this large cohort of postmenopausal women we have confirmed the strong positive associations of abdominal aortic aneurysm events with age and smoking and the negative association with diabetes, previously reported in men.[@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref10]

Previous screening studies that used ultrasonography have reported factors associated with abdominal aortic aneurysm in 3000-3500 women each,[@ref2] [@ref3] [@ref6] [@ref9] but the numbers found to have abdominal aortic aneurysm (1-2%) were too small to generate robust models with more than a few independent variables.[@ref15] Similarly, a recent report of the Life Line screening programme included 10 012 women but detected only 74 aneurysms.[@ref12] Previous clinical diagnosis studies from Chicago and northern California identified 109 and 115 abdominal aortic aneurysm events in women, respectively,[@ref10] [@ref11] though only the northern California study provided multivariable models by sex.[@ref11] Strong associations with abdominal aortic aneurysm in women were found in all these studies for age and smoking and in some for coronary and cerebral vascular disease, and weaker associations were seen in most for height, hypertension, and high cholesterol.

A negative association between abdominal aortic aneurysm and diabetes was described more than a decade ago,[@ref4] [@ref16] and, though confirmed in various studies in men,[@ref5] [@ref17] whether it occurs in women has been uncertain. Several studies found marked negative trends in women,[@ref2] [@ref9] [@ref11] but these did not reach significance. The Life Line screening programme did not observe a negative trend,[@ref12] and the Chicago clinical diagnosis study reported a significant univariable interaction between sex and diabetes, with a positive univariable association for women but a negative trend for men.[@ref10] In our large study we examined factors associated with abdominal aortic aneurysm in women and found a significant negative association with diabetes. No adequate explanation of the mechanism of this negative association has yet emerged,[@ref18] but the observation adds to the evidence for a common pathophysiology of abdominal aortic aneurysm in men and women and for a fundamental difference between aneurismal and occlusive vascular disease.[@ref19]

We observed a negative association between postmenopausal hormone therapy and aortic aneurysm, which was significant for use at time of enrolment and for duration of use over five years. There is some precedent in the literature for this association: the northern California study reported a non-significant trend in the same direction,[@ref11] and a recent review of animal data found evidence for "a possible role for estrogen in protection against abdominal aortic aneurysm."[@ref8] On the other hand, 33 of the 184 aneurysm events described in our analysis have been included in previous publications from the women's health initiative, and these reported hormone therapy effects from the randomised trials that differ from the effects we observed from hormone therapy used before enrolment. Women randomised to hormone therapy had significantly more abdominal aortic aneurysm events than controls in the Estrogen Alone trial (14 *v* 6 cases, hazard ratio 2.4)[@ref20] and a number similar to controls in the Estrogen plus Progesterone trial (7 *v* 6, hazard ratio 1.1).[@ref21] Possible sources of discrepancies between baseline and randomised effects of hormone therapy in the women's health initiative have been reviewed and include both greater duration of treatment and possible confounding by differences in lifestyle in the baseline data.[@ref22] Further studies will be needed to clarify the effect of hormone therapy on aortic aneurysm.

The small but significant association we found between height and aortic aneurysm has been seen in previous studies in both men and women,[@ref4] [@ref5] [@ref9] [@ref10] [@ref11] even when abdominal aortic aneurysm was defined relative to the suprarenal aorta rather than by unadjusted diameter,[@ref4] though to our knowledge no explanation for this association has been proposed. Neither our study nor the northern California study[@ref11] provide support for a recent report of an association between alcohol consumption and abdominal aortic aneurysm.[@ref23]

It remains unclear why prevalence of abdominal aortic aneurysm differs so much by sex, even after multivariable adjustment for known associations. These adjustments might have been incomplete or there might be an as yet undiscovered biological explanation, possibly related to sex steroid hormones. Regardless, the negative association of abdominal aortic aneurysm with diabetes seems to be common to both sexes.

What is already known on this topic
-----------------------------------

1.  Abdominal aortic aneurysm is more common in men but more deadly in women

2.  Most previous studies have included too few women with aortic aneurysm to generate robust multivariable models

What this study adds
--------------------

1.  There are strong positive associations between age and smoking and clinically important abdominal aortic aneurysm in women

2.  The negative association between abdominal aortic aneurysm and diabetes previously reported in men is also seen in women
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